Table 3B.
Genotype-by-treatment interaction results for genetic model (additive and dominant) among African Americans.
| Out-come | AGT variant | Number of cases (col %) | ORs and p-values for genetic model, African Americans | |||||
|---|---|---|---|---|---|---|---|---|
| CHL | AML | LIS | CHL vs. AML | CHL vs. LIS | LIS vs. AML | |||
| CHD (n = 753) | rs7079 | CC | 259 (78.3%) | 175 (87.1%) | 175 (85.0%) | p = 0.01; OR = 1.9; CI(1.1–3.0) | p = 0.06; OR = 1.6; CI (1.0–2.5) | p = 0.54; OR = 1.2; CI(0.7–2.1) |
| AC&AA | 72 (21.7%) | 26 (12.9%) | 31 (15%) | |||||
| rs5051 | TT | 237 (71.6%) | 150 (73.2%) | 162 (78.3%) | p = 0.69; OR = 1.1; CI(0.7–1.6) | p = 0.09; OR = 1.4; CI(1.0–2.1) | p = 0.23; OR = 0.8; CI(0.5–1.2) | |
| TC&CC | 94 (28.4%) | 55 (26.8%) | 45 (21.7%) | |||||
| rs3789678 | CC | 215 (64.6%) | 139 (69.9%) | 126 (60.9%) | p = 0.21; OR = 1.3; CI(0.9–1.9) | p = 0.39; OR = 0.9; CI(0.6–1.2) | p = 0.06; OR = 1.5; CI(1.0–2.2) | |
| TC&TT | 118 (35.4%) | 60 (30.1%) | 81 (39.1%) | |||||
| rs2493133 | CC | 211 (64.5%) | 134 (68.7%) | 145 (71.1%) | p = 0.33; OR = 1.2; CI(0.8–1.8) | p = 0.12; OR = 1.4; CI(0.9–2.0) | p = 0.61; OR = 0.9; CI(0.6–1.4) | |
| TC&TT | 116 (35.5%) | 61 (31.3%) | 59 (28.9%) | |||||
| rs2493129 | GG | 288 (86.0%) | 164 (82.4%) | 180 (86.5%) | p = 0.27; OR = 0.8; CI(0.5–1.2) | p = 0.85; OR = 1.0; CI(0.6–1.7) | p = 0.25; OR = 0.7; CI(0.4–1.3) | |
| AG&AA | 47 (14%) | 35 (17.6%) | 28 (13.5%) | |||||
| rs2478544 | GG | 96 (31.3%) | 48 (25.7%) | 63 (32.1%) | p = 0.31; OR = 0.9; CI(0.7–1.1) | p = 0.97; OR = 1.0; CI(0.8–1.3) | p = 0.34; OR = 0.9; CI(0.7–1.2) | |
| GC | 144 (47.0%) | 96 (51.3%) | 89 (45.4%) | |||||
| CC | 67 (21.8%) | 43 (23.0%) | 44 (22.5%) | |||||
| rs11122576 | AA | 294 (87.5%) | 191 (94.6%) | 181 (87.0%) | p = 0.006; OR = 2.5; CI(1.2–4.9) | p = 0.87; OR = 1.0; CI(0.6–1.6) | p = 0.01; OR = 2.6; CI(1.2–5.4) | |
| AG&GG | 42 (12.5%) | 11 (5.5%) | 27 (13%) | |||||
| HF (n = 634) | rs7079 | CC | 190 (80.9%) | 181 (86.2%) | 154 (86.0%) | p = 0.13; OR = 1.5; CI(0.9–2.5) | p = 0.16; OR = 1.5; CI(0.9–2.5) | p = 0.96; OR = 1.0; CI(0.6–1.8) |
| AC&AA | 45 (19.1%) | 29 (13.9%) | 25 (14%) | |||||
| rs5051 | TT | 157 (67.1%) | 160 (76.2%) | 125 (69.8%) | p = 0.03; OR = 1.6; CI(1.0–2.4) | p = 0.55; OR = 1.1; CI(0.7–1.7) | p = 0.16; OR = 1.4; CI(0.9–2.2) | |
| TC&CC | 77 (32.9%) | 50 (23.8%) | 54 (30.2%) | |||||
| rs3789678 | CC | 147 (62.8%) | 124 (60.5%) | 100 (55.9%) | p = 0.59; OR = 0.9; CI(0.7–1.3) | p = 0.16; OR = 0.8; CI(0.6–1.1) | p = 0.38; OR = 1.2; CI(0.8–1.6) | |
| TC | 76 (32.5%) | 70 (34.2%) | 68 (38.0%) | |||||
| TT | 11 (4.7%) | 11 (5.4%) | 11 (6.2%) | |||||
| rs2493133 | CC | 145 (62.5%) | 142 (69.3%) | 117 (66.5%) | p = 0.14; OR = 1.4; CI(0.9–2.0) | p = 0.41; OR = 1.2; CI(0.8–1.8) | p = 0.56; OR = 1.1; CI(0.7–1.8) | |
| TC&TT | 87 (37.5%) | 63 (30.7%) | 59 (33.5%) | |||||
| rs2493129 | GG | 207 (87.7%) | 189 (89.2%) | 143 (80.3%) | p = 0.64; OR = 1.2; CI(0.6–2.1) | p = 0.04; OR = 0.6; CI(0.3–1.0) | p = 0.02; OR = 2.0; CI(1.1–3.6) | |
| AG&AA | 29 (12.3%) | 23 (10.9%) | 35 (19.7%) | |||||
| rs2478544 | GG | 72 (32.6%) | 56 (28.4%) | 63 (38.7%) | p = 0.56; OR = 0.9; CI(0.7–1.2) | p = 0.35; OR = 1.1; CI(0.9–1.5) | p = 0.14; OR = 0.8; CI(0.6–1.1) | |
| GC | 105 (47.5%) | 102 (51.8%) | 69 (42.3%) | |||||
| CC | 44 (20.0%) | 39 (19.8%) | 31 (19.0%) | |||||
| rs11122576 | AA | 214 (91.1%) | 196 (92.9%) | 161 (89.0%) | p = 0.48; OR = 1.3; CI(0.6–2.6) | p = 0.47; OR = 0.8; CI(0.4–1.5) | p = 0.18; OR = 1.6; CI(0.8–3.3) | |
| AG&GG | 21 (8.9%) | 15 (7.2%) | 20 (11%) | |||||
CHL, chlorthalidone; AML, amlodipine; LIS, lisinopril; CHD, coronary heart disease; HF, heart failure.
Dominant model was used for SNP which has any cell size less than 10 observations by collapsing minor allele homozygotes with heterozygotes which was compared to common allele homozygotes. Additive model coded common homozygotes as 0, heterozygotes as 1; rare homozygotes as 2; and assumed linearity (1-degree of freedom test).